GLIMEPIRIDE-INDUCED LEUKOCYTOCLASTIC VASCULITIS: A RARE CASE REPORT AND INSIGHT OF THE 1990 ACR CRITERIA FOR THE DIAGNOSIS OF LEUKOCYTOCLASTIC VASCULITIS

Cutaneous drug-induced leukocytoclastic vasculitis accounts for about 10% of all vasculitis cases and usually presents as skin lesions in a palpable purpuric form that likely begins within two weeks after exposure to a particular agent. The use of glimepiride has recently increased with the sharp augmentation of poorlycontrolled diabetes mellitus cases, and hence, recognition of this reaction is important as it may lead to fatal consequences, and discontinuation of the offending drug is a cornerstone of the management. To the best of our knowledge, this is the first reported case of Glimepiride-induced leukocytoclastic vasculitis from the Eastern Part of India.